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BMI body mass index
CVD cardiovascular disease
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OGTT oral glucose tolerance test
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TXA2 thromboxane A2
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8I INTRODUCTION
Pre-eclampsia is a pregnancy-specific multisystem disorder characterised by reduced
placental perfusion, vascular endothelial dysfunction, and activation of the
coagulation cascade (Roberts and Redman 1993).  Hypertension and proteinuria are
the clinical symptoms of pre-eclampsia which are easiest to recognise.  Pre-
eclampsia is predominantly a disease of primigravidae, characterised also by typical
renal lesions, which disappear after delivery.  Occurring in approximately 3% of
pregnancies in the western world (Saftlas et al. 1990), it is one of the leading causes
of maternal death (Grimes 1994).
The insulin resistance syndrome, a cluster of metabolic changes including insulin
resistance, glucose intolerance, hyperinsulinaemia, hypertriglyceridaemia, decreased
high-density lipoprotein (HDL) cholesterol, and hypertension, is a powerful risk factor
as regards cardiovascular disease (CVD) (Reaven 1988).  Most of these metabolic
changes are also observed in pre-eclampsia (Kaaja et al. 1995, Hubel et al. 1996,
Lorentzen et al. 1998).  Another factor possibly affecting endothelial function, an
elevated plasma homocysteine concentration, appears to indicate an increased risk
of CVD in later life in men and non-pregnant women (Graham et al. 1997).  It is also
known that endocrine disorders, such as polycystic ovary syndrome (PCOS) and
non-insulin-dependent diabetes mellitus (NIDDM) are associated with insulin
resistance (Davidson 1995).  Both of these diseases are also associated with an
increased risk of pre-eclampsia (Berkowitz 1998).  All this may imply that there could
be a connection between insulin resistance and pre-eclampsia.
9II REVIEW OF THE LITERATURE
1. Pre-eclampsia
1.1 Definitions
The American College of Obstetricians and Gynecologists (1972) recommended
classification of hypertension during pregnancy into chronic hypertension, pre-
eclampsia, pre-eclampsia superimposed on chronic hypertension, and transient
hypertension.  Later, two international committees used slightly different definitions
for pre-eclampsia (Table 1).  In addition to elevated blood pressure and proteinuria,
impaired liver function, increased serum uric acid, decreased platelet count, and
symptoms and signs, such as headache, visual disturbances, epigastric pain, and
pulmonary oedema are considered particularly ominous (Gifford et al. 1990).  Most
investigators consider pre-eclampsia and transient hypertension to be distinct
syndromes (Chesley 1980).  Although the latter may also be a pre-proteinuric phase
of pre-eclampsia, it can be a recurrence of chronic hypertension which abated in mid-
pregnancy, or a manifestation of latent essential hypertension (Gifford et al. 1990).
Table 1. The definition of pre-eclampsia according to two international committees
The International Society for the Study of Hypertension in Pregnancy (Davey and
MacGillivray 1988)
Pre-
eclampsia
Hypertension and proteinuria developing during pregnancy, labour, or
puerperium in a previously normotensive nonproteinuric woman
Hypertension A. Diastolic blood pressure of ≥ 110 mm Hg on any one occasion, or
B. Diastolic blood pressure of ≥ 90 mm Hg on two occasions ≥ 4 hours
apart
The diastolic blood pressure is taken as the point of muffling (phase IV) of
the Korotkoff sounds
Proteinuria Total protein ≥ 0.3 g in one 24-hour urine collection
Two “clean-catch-midstream“ or catheter specimens of urine collected ≥ 4
hours apart with
1. 1 g albumin per litre or ≥ 2+ on reagent strip
2. 0.3 g albumin per litre or 1+ on reagent strip in a sample of specific
gravity < 1.03 and pH <8
National High Blood Pressure Education Program Working Group (Gifford et al. 1990)
Pre-
eclampsia
Increased blood pressure accompanied by proteinuria, edema, or both
Hypertension ≥140/90 mm Hg after 20 weeks’ gestation
Systolic blood pressure increases ≥30 mm Hg, or diastolic blood pressure
increases ≥15 mm Hg
Proteinuria ≥ 0.3 g in a 24-hour specimen
≥1+ on dipstick
Edema Clinically evident swelling
Rapid increase in weight
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1.2 Pathogenesis and risk factors
Pre-eclampsia has been called “a disease of theories“ which well depicts the fact that
the aetiology of pre-eclampsia has remained poorly understood (Table 2).  Yet
growing evidence indicates genetic or immunological conflicts between the mother
and the fetus as aetiological factors of this disease (Dekker and Sibai 1998).  Pre-
eclampsia is increased in association with oocyte donation, when the foetus
genetically differs from the mother (Söderström-Anttila et al. 1998), and when a man
has already fathered a pre-eclamptic pregnancy (Lie et al. 1998).  In some studies
barrier contraceptive use (Klonoff-Cohen et al. 1989) and donor insemination (Smith
et al. 1997) are also predisposing factors as regards pre-eclampsia, although
contradicting data also exists (Mills et al. 1991, Laivuori et al. 1998).  It is equally
clear that the placenta and maternal constitutional factors contribute to the aetiology
of this disease (Roberts 1998).
Table 2. Some modern hypotheses of the aetiology of pre-eclampsia
Immunological maladaptation (Redman 1991)
Genetic disease (Cooper et al. 1993)
Placental ischaemia, increased trophoblast deportation (Smarason et al.
1993)
Very-low-density lipoprotein-toxicity (Arbogast et al. 1994)
Distinct placental and maternal genesis, endothelial injury is
the point of convergence
(Ness and Roberts
1996)
Excessive maternal inflammatory response to pregnancy (Redman et al. 1999)
1.2.1 Placental factors and endothelial dysfunction
Pre-eclampsia can develop without a foetus as is the case in hydatidiform mole
(Gifford et al. 1990).  A theory regarding the placenta as a primary origin of pre-
eclampsia stems from evidence that a poorly perfused placenta releases humoral
factor(s) that bring(s) about endothelial cell activation in the placental and maternal
vascular bed, leading to the onset of pre-eclampsia (Roberts et al. 1989).  In normal
pregnancy maternal decidual arteries undergo vasodilatation to increase blood flow
to the intervillous space (Craven et al. 1998).  Immunohistochemical studies have
confirmed that initial stages of these alterations occur in the absence of cellular
interaction with extravillous cytotrophoblasts as a maternal response to pregnancy
(Craven et al. 1998).  Later, placental cytotrophoblasts invade the uterus and
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undergo transformation of their phenotype to acquire endothelial cell characteristics,
which could be critical to endovascular invasion (Zhou et al. 1997).
In pregnancies doomed to become pre-eclamptic, trophoblastic invasion does not
occur normally.  Thus, increased vascular resistance and reduced placental
perfusion ensue, which are important early features of pre-eclampsia (Roberts 1998).
A primary defect may be a failure of trophoblasts to obtain an endothelial phenotype
(Zhou et al. 1997).  On the other hand, the reduced placental perfusion may also be
a consequence of excessive placental size, as in multiple gestation (Ros et al. 1998),
or of hydropic placentas and hydatidiform moles (Gifford et al. 1990), which
conditions are often accompanied by an increased risk of pre-eclampsia (Ness and
Roberts 1996).  Some chromosomal abnormalities such as trisomy 13 (Tuohy and
James 1992), or triploidy (Rijhsinghani et al. 1997) also increase the risk of pre-
eclampsia.
Endothelial dysfunction has been considered central in the pathophysiology of pre-
eclampsia (Roberts et al. 1989).  In this regard, placental cytokines, lipid peroxides,
syncytiotrophoblast microvesicles and fluid shear stress, which activate endothelial
cell function, may be crucial (Roberts 1998).  Cultured villous explants from the
human placenta incubated in hypoxic conditions increase the production of
immunoreactive cytokines, such as tumour necrosis factor-alpha (TNF-α) and
interleukin-1 (IL-1) (Benyo et al. 1997).  Indeed, plasma levels of TNF-α and IL-6 are
elevated in pre-eclampsia (Kupferminc et al. 1994, Conrad et al. 1998).  It is also
known that the placenta is rich in polyunsaturated fatty acids (Ogburn et al. 1988),
and thus could serve as a source of lipid peroxides, which are secreted into the
maternal circulation (Walsh and Wang 1993).  Lipid peroxidation is increased, and
the activity of antioxidant enzymes is decreased in pre-eclamptic placentae (Poranen
et al. 1996).  Lipid peroxides damage endothelial cells, inhibit the synthesis of
prostacyclin (PGI2) and increase the production of thromboxane (TxA2), which is a
potent vasoconstrictor and stimulator of platelet aggregation (Mäkilä et al. 1984,
Walsh 1998).  Furthermore, the production of vasoconstrictive endothelin (ET)-1 is
increased in pre-eclampsia (Taylor et al. 1990, Ranta et al. 1999), whereas the role
of vasodilatory nitric oxide in pre-eclampsia is still controversial (Ranta et al. 1998).
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1.2.2 Maternal factors
Although placental hypoperfusion and other placental factors evidently are important
components in the aetiology of pre-eclampsia, they cannot alone account for the
disease.  This is supported, for example, by the fact that only 30% of infants of pre-
eclamptic women are growth-retarded (Eskenazi et al. 1993).  On the other hand,
pre-eclampsia-like trophoblastic changes are also seen in pregnancies complicated
by intrauterine growth retardation without pre-eclampsia (Khong et al. 1995).  There
are indeed several maternal factors which clearly predispose to pre-eclampsia (Table
3).  These factors, e.g. dyslipidaemia in diabetes and renal changes in hypertension,
may also have direct effects on endothelial cells (Ness and Roberts 1996).
Hyperinsulinaemia and deficiency of vasodilatory PGI2 are present in hypertensive
pregnant women (Kaaja et al. 1995).  It is also known that hyperlipidaemic sera from
pre-eclamptic women induce triglyceride accumulation in cultured endothelial cells
and reduce PGI2 release (Lorentzen et al. 1991).  Moreover, the higher ratio of free
fatty acids (FFAs) to albumin and increased lipolytic activity in sera from pre-
eclamptic women result in enhanced endothelial uptake of FFAs (Endresen et al.
1992).
Table 3. Maternal factors predisposing to pre-eclampsia, Odds ratio (95%
confidence interval) or relative risk
Family history of pre-eclampsia 2- to 5-fold (Chesley and Cooper
1986)
Collagen vascular disease 3-4-fold (Kaaja et al. 1990)
Migraine 2.4 (1.4-4.2) (Marcoux et al. 1992)
Gestational diabetes mellitus 3-fold (Suhonen and Teramo
1993)
Hyperthyroidism (uncontrolled) 4.7 (1.1-19.7) (Millar et al. 1994)
Chronic hypertension 9-fold (Rey and Couturier 1994)
Primiparity 3.8 (2.8-5.2) (Mittendorf et al. 1996)
Elevated systolic blood pressure
(during early pregnancy)
2.7 (1.7-4.3) (Sibai et al. 1997)
Elevated diastolic blood pressure
(during early pregnancy)
1.7 (1.3-2.2) (Sibai et al. 1997)
Polycystic ovary syndrome 5-6-fold (de Vries et al. 1998)
Renal disease 7.2 (4.2-12.5) (Fink et al. 1998)
Insulin- dependent diabetes
mellitus
5.6 (2.7-11.4) (Ros et al. 1998)
Obesity 5.2 (2.4-11.5) (Ros et al. 1998)
Maternal low birth weight 5.2 (1.2-21.5) (Innes et al. 1999)
Maternal preterm birth 3.6 (1.3-10.3) (Innes et al. 1999)
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1.2.3 Familial tendency
A familial tendency in pre-eclampsia is well-established (Cooper et al. 1993).  This
information dates back to a classic study by Chesley and Cooper (1986), who found
pre-eclampsia in 26% of the daughters and 16% of the granddaughters of eclamptic
mothers (Chesley and Cooper 1986).  Major dominant gene model with reduced
penetrance or multifactorial inheritance have been considered the best working
hypotheses (Arngrimsson et al. 1995).  However, although a twin study failed to
detect concordant monozygotic twins (Thornton and Onwude 1991), the reduced
penetrance model, in which the fetal genotype modifies expression of the maternal
genotype, could explain the existence of discordant monozygotic twins (Harrison et
al. 1997).
At present several groups are conducting linkage studies and complete maternal
genome-wide scans in order to discover pre-eclampsia genes.  However, so far no
such genes have been identified (Harrison et al. 1997).  The hunt for genes for pre-
eclampsia will yield many that may operate as risk factors (Redman et al.1999).  An
increased risk of pre-eclampsia has been associated with certain polymorphisms and
mutations, e.g. in the angiotensinogen gene (Ward et al. 1993), in the factor V gene
(Lindoff et al. 1997), and in the methylenetetrahydrofolate reductase gene (Sohda et
al. 1997).  Polymorphisms and mutations in these diverse genes may be related to
pre-eclampsia, because all of them are cardiovascular risk factors.  It is obvious that
the list of gene mutations thought to be of significance in the aetiology of pre-
eclampsia will expand greatly in future.
2. Insulin resistance and insulin resistance syndrome
Insulin resistance is defined as an impaired ability of insulin to stimulate the uptake
and disposal of glucose by muscle (Reaven et al. 1996).  Reaven was the first to
describe so-called Syndrome X (insulin resistance syndrome) which denotes a
cluster of decreased insulin sensitivity, glucose intolerance, hyperinsulinaemia,
increased very low-density lipoprotein (VLDL) triglyceride, decreased HDL
cholesterol, and hypertension (Reaven 1988).  Later on, other conditions, such as
hyperuricaemia (Facchini et al. 1991), a high plasminogen activator inhibitor-1 level
(Juhan-Vague et al. 1991, Vuorinen-Markkola and Yki-Järvinen 1994), small, dense
low-density lipoprotein (LDL) particles (Reaven et al. 1993, Selby et al. 1993),
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obesity, particularly upper body obesity (Landsberg 1996), and microalbuminuria
(Mykkänen et al. 1998) have been added to elements of the insulin resistance
syndrome.  Insulin resistance is a common phenomenon, occurring in approximately
25% of the general population, and it is associated with an increased risk of CVD
(Reaven 1994).
Several genetic and metabolic factors have been linked to insulin resistance
(Table 4).  Gestational diabetes mellitus (GDM) (Clark et al. 1997), hyperleptinaemia
(de Courten et al. 1997, Leyva et al. 1998), and PCOS (Davidson 1995) may also be
manifestations of the insulin resistance syndrome.  Genes are evidently closely
associated with the control of insulin action, as in NIDDM concordance rate
estimatefor monozygotic twins is 34% in twin pairs (Kaprio et al. 1992).
Table 4. Causes of insulin resistance (Moller and Flier 1991)
Defects intrinsic to target cells
Mutations in the insulin receptor gene
Defects in other genes important for insulin action
Secondary factors affecting target cells
Abnormal physiological states
Stress (e.g. fever, sepsis)
Fasting or starvation
Uraemia
Cirrhosis
Ketoacidosis
Obesity
Diabetes or hyperglycaemia
Normal physiological states
Puberty
Advanced age
Pregnancy
Specific hormonal or metabolic factors
Glucocorticoids (e.g. Cushing’s syndrome)
Growth hormone (acromegaly)
Catecholamines (e.g. pheochromocytoma)
Glucagon (e.g. glucagonoma)
Thyroid hormone (e.g. thyrotoxicosis)
Hyperinsulinaemia (e.g.insulinoma)
Hyperglycaemia (e.g.diabetes)
Non-esterified fatty acids
Adenosine
Islet amyloid polypeptide (amylin)
Autoantibodies to insulin receptor
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2.1 Measurement of insulin sensitivity
In clinical practice the measurement of insulin sensitivity is not easy.  Increased
insulin concentrations in peripheral blood generally reflect insulin sensitivity in non-
diabetic subjects (Laakso 1993).  However, insulin levels also depend on secretion,
distribution, and degradation of insulin in addition to tissue insulin sensitivity
(Ferrannini and Mari 1998).  The measurement of insulin sensitivity by use of
hyperinsulinaemic euglycaemic clamp, the insulin suppression test, or the frequently
sampled intravenous glucose tolerance test (the Minimal Model approach) are
suitable for study purposes but not for clinical practice as they are expensive and
have limited patient acceptance (Haffner and Miettinen 1997).
The euglycaemic hyperinsulinaemic clamp, the best standard for the
measurement of insulin action, involves a constant insulin infusion while maintaining
euglycaemia by infusing a variable amount of glucose (DeFronzo et al. 1979).  The
glucose infusion rate provides a quantitative assessment of the biological effect of
insulin.  The clamp can be combined with a number of other procedures when
studying non-pregnant subjects (Ferrannini and Mari 1998).  It requires two
intravenous lines, on-line plasma glucose determination, and arterialized blood,
commonly accomplished by retrograde cannulation of a heated wrist or hand vein
(Ferrannini and Mari 1998).  At the end of the clamp study, the subject’s plasma
glucose must be monitored for some time because the hypoglycaemic effect extends
beyond the return of plasma insulin to its baseline value (Ferrannini and Mari 1998).
The insulin suppression test is a reverse clamp, in which exogenous glucose
infusion is kept constant while the plasma glucose concentration is allowed to vary: at
a steady state, the higher the level of blood glucose, the worse the insulin sensitivity
(Ferrannini and Mari 1998).  Because hyperglycaemia will stimulate endogenous
insulin release, the β-cell response must be suppressed by means of somatostatin
(Harano et al. 1977).  In this method some problems may arise: plasma glucose may
not stabilize satisfactorily over the infusion period, steady state plasma glucose in
insulin-resistant individuals may exceed the renal threshold leading to glucosuria,
and somatostatin may inhibit the secretion of hormones other than somatostatin
(Ferrannini and Mari 1998).
In the Minimal Model an intravenous glucose injection is followed by frequent
determinations of plasma glucose and insulin (Bergman 1989).  A computer program
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allows calculation of insulin sensitivity from the dynamic relationships between the
plasma glucose and insulin concentration curves.  Minimal Model analysis of
frequently sampled intravenous glucose tolerance test requires a discrete insulin
response, and therefore the protocol includes an exogenous infusion of insulin 20
minutes after the injection of the glucose bolus (Saad et al. 1994).  In severe insulin
resistance the minimal model may yield negative values for insulin sensitivity (Saad
et al. 1994).  In addition, it has some drawbacks: a need for two intravenous lines,
frequent blood sampling, and a risk of hypoglycaemia, which might occur late in the
test.  Moreover, this method demands the investigator’s confidence in a ‘black box‘ of
calculations (Ferrannini and Mari 1998).  Nevertheless, the Minimal Model is
regarded as a representative model, because it gives comparable results with those
obtained with the clamp method (Saad et al. 1994).
2.2 Implications of insulin resistance
As many as 50% of non-pregnant patients with essential hypertension appear to be
insulin resistant and hyperinsulinaemic (Zavaroni et al. 1992).  Hypertensive patients
have enhanced plasma glucose and insulin responses to an oral glucose challenge
(Shen et al. 1988).  The higher plasma concentrations of glucose and insulin in these
patients result from insulin resistance in peripheral tissues (Ferrannini et al. 1987).
Increased sympathetic tone, present in approximately 30% of patients with
hypertension, is closely associated with the insulin resistance syndrome, and could
be the primary factor of the syndrome (Julius 1998).  The significance of insulin
resistance and hyperinsulinaemia preceding the onset of hypertension has also been
questioned, e.g. in view of the absence of hypertension in a number of populations
with other elements of insulin resistance syndrome (Mark and Anderson 1995).
Dyslipidaemia in insulin resistance comprises elevated plasma triglycerides,
decreased HDL cholesterol, compositional changes in HDL subclasses,
preponderance of small, dense LDL cholesterol, and enhanced postprandial lipaemia
(Taskinen 1995).  The failure of insulin to suppress VLDL production in the liver may
be the central perturbation that leads to the elevation of circulating triglyceride
particles in insulin-resistant states (Frayn 1993, Sparks and Sparks 1993).  The
increased flux of FFAs to the liver is an important contributing factor indicating that
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the release of FFAs from triglyceride stores is not adequately suppressed by insulin
(Björntorp 1994).
Obesity is characterised by elevated FFA concentrations and enhanced lipid
oxidation (Groop et al. 1992).  Even small increments in body mass index (BMI) and
waist-to-hip ratio, as often seen in hypertension, impair insulin sensitivity, probably
through altered lipid metabolism (Toft et al. 1998).  Obesity, particularly visceral
adiposity with increased FFA flux into the portal circulation, is associated with insulin
resistance (DeFronzo and Ferrannini 1991, Karter et al. 1996).  Visceral obesity has
a stronger association to metabolic and cardiovascular disease than total weight
(Kaplan 1989).  Women with upper body obesity also have higher androgen
production rates and higher circulating free testosterone and free oestradiol
concentrations (Kirschner et al. 1990), which may be a consequence of insulin-
induced promotion of ovarian androgen secretion (Pasquali et al. 1993).  Insulin
resistance precedes NIDDM, but it is not known whether it reflects the strongest risk
factor or whether it unmasks a primary β-cell defect (Yki-Järvinen 1994).
In late 1970s the result of three epidemiological prospective studies indicated that
hyperinsulinaemia predicts the development of symptomatic CVD in men (Welborn
and Wearne 1979, Ducimetiere et al. 1980, Pyörälä et al. 1985). An association
between hyperinsulinaemia and CVD in women was reported in 1998 (Bonora et al.
1998).  The mechanism(s) by which the insulin resistance syndrome and
hyperinsulinaemia may cause CVD may be related to endothelial dysfunction and
disturbancies in coagulation.  Insulin resistance is associated with impaired
fibrinolysis (Juhan-Vague et al. 1991), blunted endothelium-dependent vasodilatation
(Steinberg et al. 1996), reduced PGI2 production, increased TXA2 production,
increased coagulation, and platelet activation (McCarty 1995).  Acute-phase
cytokines, such as IL-6 and TNF-α could underlie the associations of insulin
resistance with coagulopathy, endothelial dysfunction, and CVD (Yudkin 1999).
Endothelial dysfunction might also precede insulin resistance.  This is supported
by the fact that endothelial injury may cause a loss of glycosaminoglycan and
lipoprotein lipase (LPL, an enzyme hydrolyzing triglycerides) at the endothelial
surface (Pinkney et al. 1997).  Dysfunction of LPL has been shown to lead to
increased plasma triglyceride concentrations and reduced HDL cholesterol (Reymer
et al. 1995).  HDL cholesterol may stimulate endothelial cell function, e.g. by
stimulating PGI2-release from vascular endothelium (Pomerantz et al. 1985,
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Tamagaki et al. 1996).  This hypothesis may explain why the dyslipidaemia of insulin
resistance is confined to triglycerides and HDL.
3. Carbohydrate metabolism in pregnancy
3.1 Normal pregnancy
The levels of fasting glucose decrease, and those of fasting insulin increase in late
gestation (Catalano et al. 1992).  However, hepatic insulin sensitivity in late
pregnancy is decreased, as evidenced by a significant (30%) increase in basal
hepatic glucose production in late gestation (Catalano 1994).  An increase in
maternal plasma volume and facilitated transport of glucose from mother to fetus may
explain the decreases in fasting glucose concentrations (Kalhan et al. 1979, Catalano
1994).  The insulin response to glucose may be 3.0-3.5 times higher at 34-36 weeks’
gestation than before pregnancy (Catalano et al. 1991).  Peripheral insulin sensitivity
in late pregnancy is 33-66% decreased in comparison with the non-pregnant state
(Ryan et al. 1985, Buchanan et al. 1990, Catalano et al. 1991).  True maternal insulin
sensitivity may be even lower than the estimates presented above, because glucose
is also transported to the fetus by non-insulin-mediated pathways (Catalano 1994).
The ultimate causes and the physiological meaning of pregnancy-induced insulin
resistance are not known, but elevated FFA concentrations may be one contributing
factor (Sivan et al. 1998).  In this regard, a defect in glucose transport or
phosphorylation (Boden et al. 1994, Hawkins et al. 1997) and increased activity of
the hexosamine pathway (Hawkins et al. 1997) may be significant.  Human placental
lactogen (HPL), cortisol, and sex steroids, which are also at elevated concentrations
in pregnancy, are also likely candidates as regards the regulation of insulin sensitivity
(Ryan and Enns 1988), and, for example, HPL stimulates FFA release from adipose
tissue (Williams and Coltart 1978).
3.2 Pre-eclampsia
Pre-eclampsia is associated with increased fasting insulin concentrations and higher
glucose and insulin responses in the oral glucose tolerance test (OGTT), but the data
on insulin sensitivity are contradictory (Table 5).  It is also known that an increased
glucose response in the OGTT (Lindsay et al. 1989, Sermer et al. 1995, Joffe et al.
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1998), and elevated fasting insulin levels (Sowers et al. 1995) predict the risk of pre-
eclampsia (Table 6).
Table 5. Glucose and insulin in pre-eclamptic and normal pregnancies before and
after glucose loading
Subjects Method Findings Reference
Pre-eclamptic women,
women with gestational
hypertension,
Fasting levels of
insulin at 21-39 weeks’
gestation
Fasting insulin   ↑ (Kaaja et al.
1995)
Pre-eclamptic women Fasting levels of
glucose and insulin, 1-
hour 50g OGTT at 32
weeks’ gestation
Fasting insulin   ↑
Post-load insulin ↑
(Martinez
Abundis et al.
1996)
Pre-eclamptic women, Two-hour OGTT at 37
weeks’ gestation
Fasting glucose ↓
Post-load glucose↑
Post-load insulin ↑
(Lorentzen et
al. 1998)
Pre-eclamptic women The Minimal Model Insulin sensitivity ↑ (Roberts et al.
1998)
Women with pre-
eclampsia, gestational
hypertension (GH), and
chronic hypertension
(CH)
The euglycaemic
hyperinsulinaemic
clamp
Insulin sensitivity↓
in GH, but not in pre
eclampsia or CH
(Caruso et al.
1999)
4. Lipids and lipoproteins in pregnancy
4.1 Normal pregnancy
Normal pregnancy is characterised by progressive increases in triglyceride (300%)
and cholesterol (50%) concentrations (Potter and Nestel 1979).  In the late second
trimester increased amounts of FFAs are released into the circulation through
combined stimulation of hormone-sensitive lipase by HPL and by increased insulin
resistance (Sattar et al. 1996).  Oestrogen increases hepatic output of VLDL, and
decreases hepatic lipase activity promoting accumulation of triglycerides in
lipoproteins of densities higher than that of VLDL (Alvarez et al. 1996).  Decreased
adipose tissue LPL activity and decreased hepatic lipase activity impair the removal
of triglyceride-rich lipoproteins from the circulation (Alvarez et al. 1996), thus leading
to higher serum triglyceride concentrations.
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Table 6. Impaired glucose tolerance predicts the risk of pre-eclampsia
Subjects Method Findings Reference
Women with one
abnormal OGTT value
1-hour 50g OGTT, 3-
hour 100g OGTT at
24-32 weeks’
gestation
Elevated risk of pre-
eclampsia associated with
one abnormal OGTT value
vs. controls [OR 2.81 (1.26-
6.28)]
(Lindsay et
al. 1989)
Women with GDM,
and one abnormal
OGTT value
2-hour 75g OGTT at
28-32 weeks’
gestation
Elevated risk (3-fold) for pre-
eclampsia in women with
GDM, but not in women with
one abnormal OGTT value
(Suhonen
and Teramo
1993)
Pre-eclamptic women
Women with
gestational
hypertension
1-hour 50g OGTT at
24-32 weeks’
gestation
A 1-hour 50g OGTT value
≥ 7.8 mmol/L predicted pre-
eclampsia, but not after
adjustment for age, race,
gestational age at OGTT
and pregravid BMI
(Solomon et
al. 1994)
Women without GDM 1-hour 50g OGTT, 3-
hour 100g OGTT at
26-28
weeks’gestation
The 2-hour 100g OGTT
value was a significant
predictor of pre-eclampsia
after adjusting for BMI
(Sermer et
al. 1995)
Nulliparous women Fasting levels of
glucose and insulin
at 18-22 weeks’
gestation
Fasting levels of insulin 1.8-
fold higher in women who
developed pre-eclampsia
(Sowers et
al. 1995)
Nulliparous women
with GDM
1-hour 50g OGTT, 3-
hour 100g OGTT in
the late II trimester
The 1-hour 50g OGTT value
predicted pre-eclampsia
even in normoglycaemic
women
(Joffe et al.
1998)
4.2 Pre-eclampsia
In pre-eclampsia, triglyceride and FFA levels are markedly increased (Lorentzen et
al. 1995, Hubel et al. 1996, Murai et al. 1997), whereas total cholesterol and LDL
levels are normal, and HDL concentrations decreased (Sattar et al. 1997).
Elevations in serum triglyceride and FFA levels are already present before 20 weeks’
gestation in women with future pre-eclampsia (Lorentzen et al. 1994).  In addition,
the concentrations of triglyceride-rich lipoproteins and of small dense LDL particles
are elevated in pre-eclampsia (Sattar et al. 1997).  Furthermore it is known that
antibodies to oxidized LDL are increased in pre-eclampsia (Branch et al. 1994), but
they fail to predict the risk of this disease (Kurki et al. 1996).  It is likely that increased
hepatic lipase activity in pre-eclampsia is responsible for the reduced HDL levels
(Sattar et al. 1997).  Thus, pre-eclampsia, manifesting largely in the vascular bed in
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pregnancy is accompanied by a number of changes in lipid and lipoprotein
concentrations.
Increased plasma cytokine (IL-1, TNF-α) concentrations in pre-eclampsia resulting
from activation of macrophages/neutrophils may enhance peripheral lipolysis (Sattar
et al. 1996).  This may increase the flux of FFAs in the liver, and increase hepatic
secretion of large, triglyceride-rich VLDL particles (Sattar et al. 1996).  Free fatty
acids entering the liver are normally either subjected to β-oxidation or secreted as
triglycerides in VLDL.  An increased frequency of pre-eclampsia has been observed
in association with a β-oxidation defect, as is the case in long-chain 3-hydroxyacyl-
coenzyme A deficiency (Tyni et al. 1998).  The failure of insulin to suppress VLDL
production in the liver may also be a central perturbation in pre-eclampsia leading to
higher serum triglycerides.
5. Leptin
5.1 Leptin in a non-pregnant state
Leptin is produced almost exclusively by adipocytes (Zhang et al. 1994). It takes a
hormonal signal to the brain concerning the adequacy of energy stores, and appears
to activate the hypothalamic centres regulating energy intake and expenditure
(Mantzoros and Moschos 1998).  Serum leptin concentrations correlate highly with
percentage of body fat (Considine et al. 1996).  Gender has a major influence on
leptin levels.  Women have higher plasma leptin levels than men at any degree of
adiposity (Saad et al. 1997).  Several pieces of evidence imply that insulin increases
leptin secretion (Kolaczynski et al. 1996, Malmström et al. 1996, Utriainen et al.
1996, Boden et al. 1997, Saad et al. 1998).  Hence, in insulin resistance,
independent of adiposity, plasma leptin concentrations are elevated (Segal et al.
1996, Haffner et al. 1997).  The evidence is so strong that hyperleptinaemia has
been suggested to be part of the insulin resistance syndrome (de Courten et al.
1997).  Leptin-stimulated angiogenesis may also facilitate lipid release from fat stores
to maintain energy homeostasis (Sierra-Honigmann et al. 1998).
5.2 Leptin in pregnancy
Circulating leptin levels increase by some 100 to 200% during normal pregnancy,
reaching peak levels between 20 and 30 weeks of gestation (Sattar et al. 1998, Sivan
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et al. 1998).  These elevations may be derived from adipocytes, but placental
trophoblasts must also be taken into account as a source, since they produce leptin
(Masuzaki et al. 1997, Mise et al. 1998).  The relative contribution of these cells to
the circulating leptin pool in pregnancy is as yet unknown.  Leptin correlate with
estradiol and human chorionic gonadotrophin levels (Hardie et al. 1997).  The
physiological role of leptin in pregnancy is unknown, but it may help to guarantee
adequate circulating FFAs and glucose for the fetus (McCarthy et al. 1999).
6. Homocysteine
6.1 Homocysteine in a non-pregnant state
Homocysteine is a sulphur-containing amino acid formed from methionine (Welch
and Loscalzo 1998).  This amino acid has attracted much interest, because even
moderately elevated levels of homocysteine appear to predict CVD in men and non-
pregnant women (Stampfer et al. 1992, Graham et al. 1997).  However, this was not
observed in the North Karelia Project (Alfthan et al. 1994).  Hyperhomocysteinaemia
may damage vascular health through endothelial dysfunction, platelet activation,
procoagulation, and increased lipid peroxidation (Welch and Loscalzo 1998).  Insulin
resistance and hyperhomocysteinaemia may coexist in apparently healthy, non-
obese subjects (Giltay et al. 1998).  Patients with NIDDM have higher homocysteine
levels than non-diabetic control subjects (Chico et al. 1998).  A role for insulin
resistance in homocysteine metabolism is indicated by decreased plasma
homocysteine levels during acute hyperinsulinaemia (hyperinsulinaemic euglycaemic
clamp) in healthy subjects but not in patients with NIDDM (Fonsesca et al. 1998).
6.2 Homocysteine in pregnancy
Normal pregnancy is associated with decreased homocysteine levels (Andersson et
al. 1992), but in pre-eclamptic pregnancies such falls in homocysteine levels do not
occur (Rajkovic et al. 1997, Powers et al. 1998).  In pre-eclampsia, plasma
homocysteine concentrations are in correlation with those of plasma fibronectin, a
major cell-surface glycoprotein in endothelial cells, suggesting a role for
homocysteine in endothelial cell damage (Powers et al. 1998).
Elevated homocysteine levels have been reported in women with a history of pre-
eclampsia (Dekker et al. 1995), placental abruption or infarction (Goddijn-Wessel et
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al. 1996), unexplained recurrent pregnancy loss (Wouters et al. 1993), and in those
who have given birth to infants with a neural tube defect in previous pregnancies
(Steegers-Theunissen et al. 1994).
7. Activin A and inhibin A in pregnancy
The dimeric glycoproteins activin A and inhibin A, which were originally isolated from
ovarian follicular fluid (Ying 1988), are also produced by the decidua, placenta, and
fetal membranes (Qu and Thomas 1995).  Circulating levels of activin A and inhibin A
thus rise with advancing gestational age (Petraglia et al. 1993, Muttukrishna et al.
1995).  During pregnancy, concomitantly with activin A and inhibin A, the serum
levels of pro-αC inhibin also rise (Muttukrishna et al. 1997).  Serum concentrations of
activin A and inhibin A are increased in established pre-eclampsia (Muttukrishna et
al. 1997), but the predictive value of maternal mid-pregnancy serum levels of inhibin
A in pre-eclampsia is controversial (Cuckle et al. 1998, Räty et al. 1999).
Elevated levels of activin A in gestational diabetes (Petraglia et al. 1995) and
elevated levels of inhibin A in pregnant women with insulin-dependent diabetes
(Wallace et al. 1997), as well as the capacity of activin A to increase insulin secretion
in incubated (Verspohl et al. 1993) or perfused (Yasuda et al. 1993, Furukawa et al.
1995) rat pancreatic islets and in insulinoma cell lines (Shibata et al. 1996) implies a
connection between glucose homeostasis, activin A and inhibin A.
8. The metabolic effects of antihypertensive drugs
Antihypertensive drugs have different effects on insulin sensitivity.  Calcium channel
blockers and angiotensin-converting enzyme inhibitors are neutral in this regard,
whereas treatment with β-blockers or diuretics is associated with impaired insulin
sensitivity (Lithell 1997).  Diuretics are seldom used in pre-eclampsia, because they
may aggravate hypovolaemia and reduce placental perfusion (Lowe and Rubin
1992).  Angiotensin-converting enzyme inhibitors are contraindicated during
pregnancy, because they are associated with congenital malformations, neonatal
renal failure, intrauterine death, and reduced placental perfusion (Lowe and Rubin
1992).
Isradipine is a dihydropyridine calcium antagonist with a high affinity for slow
calcium channels.  It produces arterial vasodilatation, but does not affect cardiac
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filling pressures (Brogden and Sorkin 1995).  It has been used for treatment of
hypertension in men and non-pregnant women for years.  It has also been used for
the control of hypertension in pregnancy, and, indeed, oral administration of
isradipine at 2.5-5.0 mg twice daily has been shown to decrease blood pressure
without any deterioration in uteroplacental perfusion (Feiks et al. 1991).  Isradipine
has no effect on glucose tolerance, insulin secretion or insulin action in non-pregnant
hypertensive patients with (Klauser et al. 1991) or without NIDDM (Lind et al. 1994).
On the other hand, isradipine elevates HDL levels (Brogden and Sorkin 1995).  The
effects of isradipine on carbohydrate and lipid metabolism in pre-eclampsia are
unknown.
Metoprolol is an effective antihypertensive agent that selectively blocks β1-
receptors (Frishman and Chesner 1988).  Metoprolol, as do all β-blockers, reduces
insulin sensitivity in patients with essential hypertension (Suter and Vetter 1995), and
this reduction can be up to 15% (Lithell 1997).  Metoprolol and other β1-blockers can
also raise triglyceride levels and lower HDL cholesterol (Suter and Vetter 1995).  No
data exist on the effects of metoprolol on lipids, lipoproteins or insulin sensitivity in
pregnant women.
9. Impact of a history of pre-eclampsia on pregnancy
outcome and cardiovascular morbidity
9.1 Subsequent pregnancies
Women having had pre-eclampsia or eclampsia in their first pregnancies are at an
increased risk of a repeat this disease (Table 7), although the disease generally
occurs at a greater gestational age (Steegers and van der Post 1998).  The
recurrence risk of pre-eclampsia is best predicted by the degree of proteinuria.  The
recurrence risk of pre-eclampsia in women who had had proteinuria of 0.3-3 g/24
hours was 12.2% compared with 22.3% in women who had had proteinuria of ≥ 3
g/24 hours in their index pregnancy (Visser et al. 1999).  In general, estimation of the
risk ratio is difficult, because most of the studies lack controls, and the incidence of
eclampsia and pre-eclampsia may be different in different populations.
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Table 7. The recurrence rate of pre-eclampsia/eclampsia in women with a history
of prior pre-eclampsia/eclampsia
Country Study population % Reference
Mexico 110 eclamptic women 35.4% (Lopez-Llera and Horta
1974)
U.K. 279 pre-eclamptic women
(3507 normotensive women
7.4%
0.7%)
(Campbell et al. 1985)
Nigeria 64 eclamptic women 26.6% (Adelusi and
Ojencbede 1986)
USA 406 pre-eclamptic women
(409 normotensive women
46.8%
7.6%)
(Sibai et al. 1986)
USA 89 pre-eclamptic women 55% (Sibai et al. 1991)
USA 159 eclamptic women 24% (Sibai et al. 1992)
USA 606 pre-eclamptic women
aspirin group
placebo group
17%
19%
(Caritis et al. 1998)
9.2 Cardiovascular morbidity
Conflicting data exist on the impact of pre-eclampsia on the risk of future
hypertension.  Some researchers report that eclampsia and pre-eclampsia do not
predispose women to hypertension in later life (Chesley 1980, Fisher et al. 1981),
while others have found an increased incidence of hypertension, particularly in
women with recurrent pre-eclampsia (Sibai et al. 1991, Sibai et al. 1992).  The
incidence of hypertension has been reported to be significantly higher after 7 to 8
years (range 2 to 24 years) of follow-up in women having had pre-eclampsia in their
first pregnancy (14.8%) than in women with normotensive first pregnancy (5.6%)
(Sibai et al. 1986).  The difference increased in a subgroup followed for over 10 years
(51% in women with prior pre-eclamptic pregnancy vs. 14% in women with prior
normotensive pregnancy) (Sibai et al. 1986).
After 25 years of follow-up, 29% of deaths in women having had eclamptic first
pregnancy have been reported to be due to CVD, whereas in women having had
eclampsia as multiparas 82% of deaths were of cardiovascular-renal origin (Chesley
et al. 1976).  In Iceland the relative risk of dying from subsequent CVD was higher
among women with prior eclampsia (RR 2.61; 95% CI 1.11-6.12) and among those
with prior pre-eclampsia (RR 1.90; 95% CI 1.02-3.52) than among those with prior
hypertensive pregnancy alone (Jónsdóttir et al. 1995).  Parous women at the index
pregnancy had a twofold higher risk of dying from CVD than primigravid women (RR
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2.05; 95% CI 1.19-3.55) (Jónsdóttir et al. 1995).  These two studies imply that a
history of pre-eclamptic or hypertensive pregnancy indicated an increased risk of
CVD primarily in multiparous women.  Similar data have been reported in the UK,
where the risk of hypertensive disease (RR 2.35; 95% CI 2.08-2.65), acute
myocardial infarction (RR 2.24; 95% CI 1.42-3.53), chronic ischaemic heart disease
(RR 1.74; 95% CI 1.06-2.86), angina pectoris (RR1.53; 95% CI 1.09-2.15), and
venous thromboembolism (RR 1.62) were markedly elevated in women who had had
pre-eclampsia (Hannaford et al. 1997).
The mechanism behind the pre-eclampsia-associated impact on CVD is open.
However, decreased insulin sensitivity, as measured in Chinese women with a
history of pre-eclampsia two months postpartum by the insulin suppression test (Fuh
et al. 1995), suggested that insulin resistance could be a factor.  In another study in
African-American women 3-6 months postpartum, insulin sensitivity, as assessed by
the hyperinsulinaemic-euglycaemic clamp technique, was not different between
women with prior pre-eclampsia and controls (Jacober et al. 1994).  Different race or
different methods to assess insulin sensitivity may explain the discrepant data.
The incidence of diabetes in women with prior pre-eclamptic pregnancy (5.6%) is
also higher than in controls (3.6%) (Sibai et al. 1986).  This was also seen in another
study in both primiparous (2.5-fold) and multiparous (3.3-fold) eclamptic women after
25-year follow-up (Chesley 1976).  These data also may suggest a link between
insulin resistance and pre-eclampsia.
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III AIMS OF THE STUDY
The present studies were undertaken to investigate insulin sensitivity and its
relationships to leptin, homocysteine and activin-inhibin in pre-eclampsia.  The
specific aims were:
To compare insulin sensitivity and lipids and lipoproteins in pre-eclamptic and healthy
pregnant women during and after pregnancy
To compare the circulating levels of leptin, homocysteine, activin A and inhibin A in
pre-eclamptic and healthy pregnant women, both during and after pregnancy, and to
assess whether they are associated with insulin sensitivity
To study whether isradipine or metoprolol affect insulin sensitivity and lipid profiles in
pre-eclamptic women
To compare glucose tolerance, lipid profiles, some sex hormone levels and
endothelial function in women with a prior pre-eclamptic pregnancy, and in women
with a prior normotensive pregnancy
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IV SUBJECTS AND METHODS
1. Subjects
This study was performed with the approval of the Ethics Committee of the
Department of Obstetrics and Gynaecology, University of Helsinki.  All subjects gave
their consent after being informed of the purpose, nature and possible risks of the
studies.  Pre-eclampsia was defined as a blood pressure level ≥ 140/90 mmHg
confirmed by at least two blood pressure measurements six hours apart and
proteinuria ≥ 0.3 g/24 h urine collection between 29-39 weeks of gestation (Gifford et
al. 1990).  Severe pre-eclampsia was defined as blood pressure ≥ 160/110 mmHg,
and proteinuria ≥ 0.3 g/24 h.  Altogether, 91 subjects were studied: 8 patients
participated in both studies I-IV and V (Table 8).
Table 8. Clinical characteristics of the study population (mean±SE)
Pre-eclamptic women Controls
No. of
women
Age
(years)
BMI
(kg/m2)
No. of
women
Age
(years)
BMI
(kg/m2)
Studies I-IV
-during
pregnancy
22 30.4±1.0 22.6±0.5* 16 31.8±1.1 21.9±0.8*
-after delivery 14 23.9±0.8 11 23.5±1.0
Study V
-isradipine group 9 29.7±1.8 23.8±1.4*
-metoprolol
group
8 31.6±1.8 22.4±1.2*
Studies VI-VII
-at first
pregnancy
22 24.8±0.9 20.7±0.6* 22 25.0±0.9 19.4±0.3*
-at entry 22 41.8±0.9 23.3±0.8 22 41.8±0.9 21.9±0.4
*Pre-pregnancy body mass index (BMI)
Previously healthy, nulliparous pre-eclamptic women and 16 healthy, nulliparous
pregnant controls were recruited from maternity clinics, the prenatal clinic and the
antenatal ward between January 1, 1996 and February 28, 1998 to studies I-V.
Only the pre-eclamptic patients were hospitalised.  All women were carrying a single
foetus, and no one used antihypertensive medication, aspirin or corticosteroids.
Their glucose tolerance was confirmed to be normal by a 75 g oral glucose-tolerance
test (fasting: ≤ 4.5 mmol/L; at 1 h: ≤ 9.1 mmol/L; at 2 h ≤ 7.9 mmol/L).  None of the
controls developed hypertension during the remaining weeks of gestation.  In study
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V, patients were reinvestigated 5 to 7 days after the initiation of the antihypertensive
drug.  In studies I-III the study subjects were invited to re-examination on average 12
weeks (range 6-22 weeks) after delivery.  In studies VI-VII we investigated women
who had given birth to their first child in 1976 to 1978.
To detect 25% difference in insulin sensitivity between the medications used in the
study V with 80% power, when type 1 error (α) is 0.05, we would have needed 20
patients in each group.  This power analysis was also employed when we planned
the number of patients and controls in the study I.
Two-hour oral glucose tolerance tests were performed with 75 g glucose after an
overnight fast.  In studies I-V we measured insulin sensitivity by using a frequently
sampled intravenous glucose tolerance test with Minimal Model analysis (Bergman
1989).  After an overnight fast a bolus of glucose (0.3 g/kg body weight) was injected
intravenously at 0900 hours followed by a bolus of human insulin (VelosulinR Human,
Novo Nordisk Pharmaceuticals, Denmark, 0.03 IU/kg) 20 min later.  Blood samples
were collected as follows: 2 at baseline with a 5-minute interval, and 4, 6, 8, 10, 19,
22, 29, 37, 67, 90 and 180 minutes after administration of the glucose bolus.  Insulin
sensitivity was evaluated from disappearance curves of glucose and insulin, using
the Minimal Model computer program.  Blood and urine samples were assayed for
various agents, using established methods (Table 9)
Table 9. Characteristics of assays used (CV=intra/interassay coefficient of
variation)
Factor Source of reagents Principle of the
assay
CV(%)
Activin-A Serotec Limited, Oxford, UK Solid-phase
sandwich enzyme
immunoassay
<10 / ND
Androstenedione Antiserum from ICN Biomedica
Tracer from Amersham
RIA 6.0 / 8.5
C-peptide Byk-Sangtec Diagnostica,
Germany
RIA 3.5 / 3.6
Cholesterol  total Roche, Switzerland Enzymatic method < 0.5 / 2.1
Cholesterol HDL Boehringer Mannheim,
Germany
Precipitation of the
other lipoproteins
with heparin and
manganese chloride
4.7 / 5.4
Cholesterol HDL2 Boehringer Mannheim,
Germany
Precipitation with
0.11% dextran
sulphate
<4.0 / <6.0
Cholesterol HDL3 Boehringer Mannheim,
Germany
Non-precipitable
cholesterol
3.0 / 6.8
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Cholesterol LDL Calculated using the
Friedewald equation
DHEAS Coat-A-CountR, Diagnostic
Product Corporation, CA, USA
RIA 7.4 / 10.2
2,3 Dinor-6-keto-
prostaglandin F1α
Own antibody, tracer from
Amersham International
HPLC, RIA <8 / 10.4-14.1
2,3-Dinor
thromboxane B2
Own antibody, tracer from
Amersham International
HPLC, RIA <8 / 10.4-14.1
Endothelin-1 Own antibody, tracer from
Amersham International
RIA 5.7
FSH DELFIA, Wallac, Turku,
Finland
Fluoroimmunoassay 2.9 / 3.9
Free fatty acids E.Merck, Darmstadt,
Germany
Gas chromatograph,
methyl esther
derivatives
Glucose Merck Kebolab, Germany Ampherometric
method
- / 2.6
Homocysteine HPLC
fluorescence detection
IGFBP-1 Medix Biochemica,
Kauniainen, Finland
Immunoenzymo-
metric assay
2.9 / 6.8
Inhibin A Serotec Limited, Oxford, UK Solid-phase
sandwich enzyme
immunoassay
<10 / ND
Insulin Pharmacia, Uppsala, Sweden RIA 6.8 / 7.7
Leptin Human leptin RIA kit, Linco
Research Inc.,St. Louis, MO
RIA 3.8-4.7/-
LH DELFIA, Wallac, Turku Fluoroimmunoassay 1.8/3.4
Oestradiol Sorin Biomedica Diagnostics,
Saluggia Italy
RIA 5.7 / 5.7
Pro-αC Serotec Limited, Oxford, UK Solid-phase
sandwich enzyme
immunoassays
<10 / ND
SHBG DELFIA, Wallac, Turku,
Finland
Fluoroimmunoassay 1.5 / 4.0
Testosterone Spectria Testosterone [125I]
Coated Tube
Radioimmunoassay, Orion
Diagnostica, Espoo, Finland
RIA 5.3 / 8.9
Thyroxine ACSTM T4, Ciba Corning Competitive
immunoassay
3.2 / 6.4
Triglycerides Roche, Switzerland Enzymatic method < 0.5 / 2.0
Uric acid Boehringer Mannheim,
Germany
Enzymatic method 1.2 / 2.2
DHEAS = dehydroepiandrosteronesulphate, FSH =follicle-stimulating hormone, LH =
luteinizing hormone, IGFBP-1 = insulin growth factor-binding protein-1, RIA =
radioimmunoassay, SHBG=sex hormone-binding globulin, HPLC = high performance liquid
chromatography
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3. Statistical analysis
Continuous variables are presented as mean ± standard error of the mean (Studies I-
III and VI-VII).  In study IV glycoprotein results are presented as geometric means
and 95% confidence intervals (CIs).  In the study V data on metabolic variables,
umbilical artery resistance index and BP are presented as means and 95% CIs.
Comparisons between groups were performed with Student’s two-tailed unpaired
t test and within each group with Student’s two-tailed paired t test for variables which
were normally distributed either without or after log transformation (Studies I-VII).
Apgar score data were analysed by the Mann-Whitney non-parametric test (Study V).
Fisher’s exact probability test was used for comparisons between category variables
(Study V).  Relationships between different variables were investigated by linear and
multiple regression analysis (Studies I-VII).  Bonferroni corrections were not done for
multiple comparisons, and P<0.05 was considered significant.  A linear model taking
into account gestational age was used to investigate the relationships of
glycoproteins to different variables in study IV. The areas under the response curves
for blood glucose and serum insulin were calculated by the trapezoidal rule (Studies
I, V and VI).  Receiver-operating–characteristic (ROC) curves indicating the
diagnostic accuracy of activin A, inhibin A and pro-αC assays in pre-eclampsia were
used in study IV.  The disposition index, reflecting β-cell function in regard to insulin
sensitivity was calculated as insulin secretion (expressed as incremental area under
the insulin curve during the first ten minutes) multiplied by insulin sensitivity (Study I).
Free testosterone was calculated by using the formula: serum total testosterone in
pmol/L / 100 x (2.28-1.38 x logarithm serum sex hormone-binding globulin (SHBG) in
nmol/L / 10) (Study VII).
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V RESULTS
1. Insulin sensitivity, lipids and lipoproteins during and
after pre-eclamptic pregnancy (I)
Pre-eclamptic and control women had a similar blood glucose response in the oral
glucose tolerance test, but pre-eclamptic women’s insulin responses were
significantly higher (Figure 1).  The area under the insulin curve in pre-eclamptic
women (8221 ± 560 µU/mL x min) was 59% larger (P = 0.001) than that in the control
women (5157 ± 611 µU/mL x min).  In contrast to normal basal insulin levels, fasting
C-peptide levels in pre-eclamptic women (0.73 ± 0.04 nmol/L) were higher (P = 0.03)
than in control women (0.58 ± 0.05 nmol/L).  The C-peptide/insulin ratio showed no
difference between the two groups.
Insulin sensitivity ranged from 0.26 x 10-4 min-1⋅per µU/mL to 2.52 x 10-4 min-1⋅per
µU/mL in pre-eclamptic women, and from 0.45 x 10-4 min-1⋅per µU/ml to 3.62 x 10-4
min-1 ⋅per µU/mL in controls.  As a mean, insulin sensitivity was 37% lower (P =
0.009) in pre-eclamptic women than in controls (Figure 2 and 3).  The first 10-minute
insulin response, expressed as the area under the curve, was 53% higher in pre-
eclamptic women (971.0 ± 81.6 µU/mL x min) than in control women (633.8 ± 61.5
µU/mL x min) (P = 0.004).
Fig. 1. Levels of blood glucose and serum insulin before and following a standard
oral glucose dose (75 g) in pre-eclamptic women () and normotensive pregnant
control women (). Data are means ± SE.
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Fig. 2. Insulin sensitivity in the Minimal Model in women with pre-eclampsia and in
normotensive control women. A during pregnancy and B, 12 weeks after delivery.
Data are means ± SE.
Fig. 3. Insulin sensitivity as assessed by the Minimal Model during pregnancy and 12
weeks after delivery. P=pre-eclamptic women, C=control women
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Twelve weeks after delivery, insulin sensitivity had increased 4.6-fold in the pre-
eclamptic women (from 1.11 ± 0.15 to 5.10 ± 0.37 x 10-4 min-1⋅per µU/mL, P =
0.0001) and 3.8-fold in the controls (from 1.77 ± 0.19 to 6.86 ± 0.79 x 10-4 min-1⋅per
µU/mL, P = 0.0001).  However, postpartum insulin sensitivity in the pre-eclamptic
group was 26% lower than that in the control group (P = 0.04) (Figure 2 and 3).  No
significant correlation emerged between insulin sensitivity during pregnancy and after
delivery in the two groups.
Insulin sensitivity correlated negatively with the weeks of gestation in the pre-
eclamptic women (r = -0.53, P = 0.01), but not in the controls (r = -0.13, P = 0.64)
(Figure 4).  Insulin response to oral glucose and insulin sensitivity as measured by
the Minimal Model showed a negative correlation in the pre-eclamptic women (r= -
0.70; P=0.0004), but not in the control women (r = -0.45; P = 0.10).  Furthermore,
insulin sensitivity correlated negatively with baseline C-peptide concentrations in both
pre-eclamptic women (r = -0.62; P = 0.002) and control women (r = -0.58; P = 0.02).
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Fig. 4. The correlation between insulin sensitivity and weeks of gestation in pre-
eclamptic women () and normotensive pregnant control women ().
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In the pre-eclamptic women, serum triglyceride concentrations were 37% higher (P
= 0.004) than in the control women (3.15 ± 0.19 mmol/L vs. 2.29 ± 0.21 mmol/L), but
the levels of total and lipoprotein cholesterol did not differ (data not shown).  Serum
concentrations of HDL2 cholesterol tended to be lower in pre-eclamptic women (0.33
± 0.04 mmol/L) (P = 0.09) than in control women (0.44 ± 0.06 mmol/L).  Baseline
serum FFA concentrations were 70% higher in preeclamptic women (0.17±0.01 g/L)
than in control women (0.10 ± 0.01 g/L) (P = 0.0004), but this difference disappeared
two hours after oral intake of glucose (Figure 5).  Oral intake of glucose was
accompanied by a 38% reduction FFA in pre-eclamptic women (P = 0.0001), but only
an 18% reduction in control women (P = 0.32) (Figure 5).  In the whole study
population, insulin sensitivity was negatively related to serum concentrations of
triglycerides (r = -0.48; P = 0.002), but not to those of FFAs or total or lipoprotein
cholesterol.  In the whole study population the area under the insulin curve during the
oral glucose tolerance test was positively related to the reduction in FFAs (r = 0.43, P
= 0.015).
Fig. 5. Serum free fatty acids before and following a standard oral glucose dose (75
g) in pre-eclamptic women () and normotensive pregnant control women ().  Data
are means ± SE
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2. Serum leptin during and after pre-eclamptic
pregnancy.  Relationship to insulin sensitivity (II)
Leptin levels were significantly higher in pre-eclampsia than in normotensive
pregnancy (34.6 ± 3.9 vs. 20.0 ± 3.3 µg/L, P = 0.002).  Also leptin related to BMI in
pre-eclamptic women was higher than that in normotensive women (Figure 6).  A
positive relation between leptin and fasting insulin emerged both during pre-
eclampsia (r = 0.47, P = 0.03) and normal pregnancy (r = 0.52, P = 0.04) (Figure 7).
Insulin sensitivity was not related to leptin levels in either group of women (Figure 7).
Fig. 6. Serum leptin levels divided by body mass index (BMI) in 22 pre-eclamptic ()
and 16 control women () during pregnancy and at re-examination three months
after delivery (14 women with prior preeclampsia and in 11 women with prior
normotensive pregnancy).  Means indicated by horizontal lines.
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Fig. 7. Serum leptin in relation to serum insulin and insulin sensitivity during the third
trimester in 22 pre-eclamptic () and in 16 control pregnant women ().
There was a direct correlation between serum leptin concentration and pre-
pregnancy BMI in pre-eclamptic women (r = 0.49, P = 0.02) and in controls (r = 0.70,
P = 0.003), whereas the weight gain during pregnancy was not related to serum
leptin concentrations.  Serum leptin concentrations correlated with the degree of
proteinuria (r = 0.46, P = 0.03), but not with blood pressure or serum uric acid.
Furthermore, no relationships emerged between serum leptin and weight of the
infants or of placentas or weeks of gestation in either group.
Serum leptin levels, measured three months after delivery, had decreased
significantly in the pre-eclamptic and the control group (Figure 6).  Leptin
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concentrations tended to be higher in puerperal women with prior pre-eclampsia
(19.0 ± 3.6 µg/L) than in normal pregnancy (10.1 ± 2.0 µg/L), (P = .11).  Serum leptin
concentrations correlated with those of fasting insulin in the puerperal pre-eclamptic
group (r = 0.63, P = 0.02), and in the control group (r = 0.81, P = 0.003), and also
with insulin sensitivity in the puerperal pre-eclamptic group (r = -0.59, P = 0.02), but
not in the control group (Figure 8).  Serum leptin concentrations also correlated with
puerperal BMI in the pre-eclamptic (r = 0.74, P = 0.002) and the control group (r =
0.81, P = 0.005).
Fig. 8. Serum leptin in relation to serum insulin and insulin sensitivity 3 months after
delivery in 14 women with prior pre-eclampsia () and in 11 women with prior
normotensive pregnancy ().
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3. Plasma homocysteine during and after pre-eclamptic
pregnancy.  Relationship to insulin sensitivity (III)
Pre-eclamptic women had higher plasma homocysteine concentrations than the
controls (6.7 ± 0.4 vs. 3.8 ± 0.2 µmol/L) (Figure 9).  Three months after delivery,
levels of homocysteine (Figure 9) had increased (9.1 ± 0.6 µmol/L in the women with
prior pre-eclampsia, and 8.2 ± 0.6 µmol/L in controls), and showed no difference
between the groups.
Fig. 9. Fasting homocysteine levels in 22 pre-eclamptic () and 16 control ()
women during pregnancy and three months after delivery (14 women with prior pre-
eclampsia and 11 women with prior normal pregnancy).
In pre-eclamptic women, plasma homocysteine concentrations showed a
significant negative correlation with insulin sensitivity (r = -0.51, P = 0.02) (Figure 10),
and a significant positive correlation with the area under the curve of the first 10-
minute insulin levels (r = 0.62, P = 0.002) during the insulin-sensitivity test (Figure
10).  Control women showed no such correlations.  The increase in glucose (2.9-fold)
and in insulin (52.5-fold) during the insulin sensitivity test were not associated with
levels of homocysteine
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Fig. 10. Plasma homocysteine showed a significant negative correlation to insulin
sensitivity (left panel) and a positive correlation to the area under the first ten-minute
insulin curve (right panel) in 22 pre-eclamptic women.  Dotted lines indicate 95%
confidence intervals.
4. Serum activin A, inhibin A and pro-αC inhibin during
pre-eclamptic pregnancy.  Relationship to insulin
sensitivity (IV)
A linear model eliminating the impact of a small difference in gestational age
revealed that in pre-eclampsia activin A values were 139% higher, those of inhibin A
39% higher, and those of pro-αC 92% higher than the respective levels in the
controls.  The weekly increases were 12.5% (95% CI 6.2-19.2%) for activin A, and
4.2% (95% CI 0.1%-8.4%) for pro-αC, whereas no increase was noticed in inhibin A.
Cut-off limits were defined as the 90th percentiles of activin A, inhibin A, and
pro-αC values in normal pregnancy.  The geometric mean and 95% CI of activin A
concentrations in pre-eclampsia were 31.8 and 25.0-40.3 µg/L, respectively, and in
normal pregnancy 12.3 and 9.6-15.9 µg/L, respectively (P = 0.0001).  Seventeen
patients (77%) had elevated activin A concentrations (Figure 11).  The geometric
mean and 95% CI of inhibin A concentrations in pre-eclampsia were 1691 and 1217-
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2350 ng/L, respectively, and in normal pregnancy 882 and 703-1107 ng/L,
respectively (P = 0.003).  Ten pre-eclamptic women (46%) had elevated inhibin A
concentrations (Figure 11).  The geometric mean and 95% CI of pro-αC
concentrations in pre-eclampsia were 2.9 and 2.5-3.4 µg/L, respectively, and in
normal pregnancy 2.0 and 1.8-2.3 µg/L, respectively (P = 0.0008).  Fourteen pre-
eclamptic women (64%) had elevated pro-αC concentrations (Figure 11)
Fig. 11. Serum levels of activin A, inhibin A, and inhibin pro-αC-containing forms in
22 pre-eclamptic () and 16 control ( ) women.  Dotted lines indicate 90th
percentiles in the control group.
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Activin A, inhibin A and pro-αC concentrations were not related to insulin
sensitivity in either group.  The mean increases in blood glucose (2.9-fold) and in
serum insulin (52.5-fold) during Minimal Model testing were not associated with any
changes in activin A, inhibin A, or pro-αC concentrations, which however, were
consistently higher in pre-eclampsia (Figure 12).
Fig. 12. Levels of activin A, inhibin A and pro-αC inhibin (geometric mean and 95%
CI), blood glucose, and serum insulin (arithmetic mean and 95% CI) before and
during Minimal Model testing in 22 pre-eclamptic () and 16 control ( ) women.  1.=
Glucose at 0.3 g/kg i.v. (time 0), 2.= Insulin at 0.03 IU/kg i.v. (20 min).
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5. Insulin sensitivity, lipids and lipoproteins during
isradipine and metoprolol treatment in pre-eclamptic
pregnancy (V)
After 5 to 7 days of isradipine treatment, fasting glucose concentrations tended to
decrease [-0.12 (-0.27-0.03) mmol/L](P = 0.09), whereas no such effect was seen in
the metoprolol group [0.16 (-0.10-0.43) mmol/L] (P = 0.19).  The difference in fasting
glucose at day 5-7 was significant between the two groups (P < 0.05).  Isradipine and
metoprolol had no effect on insulin sensitivity, although the glucose response during
the first 10 minutes in the intravenous glucose tolerance test tended to decrease in
the isradipine group (P = 0.10).
High-density lipoprotein2 (HDL2) cholesterol concentrations increased in the
isradipine group by 0.07 (0.0008-0.14) mmol/L (P < 0.05), but remained unchanged
in the metoprolol group (P = 0.81).  The difference in HDL2 values between the two
groups was significant at reinvestigation: isradipine group 0.52 (0.34-0.70) mmol/L
vs. metoprolol group 0.32 (0.19-0.44) mmol/L (P < 0.05).  No significant changes
occurred among other lipids and lipoproteins in the two groups before or during
antihypertensive treatment.
Isradipine and metoprolol caused a non-significant reduction in BP.  A non-
significant decrease in the isradipine group [from 0.66 (0.60-0.71) to 0.62 (0.54-0.73),
P = 0.48] and increase in the metoprolol group [from 0.63 (0.57-0.68) to 0.66 (0.61-
0.71), P = 0.14] occurred in the umbilical artery resistance index.
6. Glucose tolerance, lipids and lipoproteins in women
with prior pre-eclamptic pregnancy (VI)
Blood glucose in the two groups at baseline and during the OGTT were comparable
(Figure 13).  In the pre-eclamptic group two women showed elevated 2-hour glucose
levels (8.6 mmol/l and 7.8 mmol/L, respectively).  Serum insulin levels in the pre-
eclamptic group were elevated at baseline (7.3 ± 0.6 vs. 5.5± 0.5 mU/L, P = 0.03), at
1 hour (45.7 ± 5.5 vs. 35.6 ± 3,5mU/L, P = 0.13), at 2 hours (32.4 ± 4.1 vs. 23.8 ± 2.3
mU/L, P = 0.08), and at 3 hours (10.1 ± 1.4 vs. 6.4 ± 0.6 mU/L, P = 0.02) (Figure 13).
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Fig. 13. Blood glucose and serum insulin (mean ± SE) before and following oral
intake of 75 g glucose in women with a history of pre-eclampsia or eclampsia () and
in control women (O).
The AUC for insulin was larger in the pre-eclamptic/eclamptic group than in the
control group (86.8 ± 9.1 vs. 65.4 ± 5.2 mU/L x h, P = 0.05) whereas the AUC for
glucose was similar in the two groups (18.2 ± 0.6 x hr vs. 17.6 ± 0.4 mmol/L x h).
The elevated basal serum insulin levels in the pre-eclamptic/eclamptic group
remained so even when insulin was adjusted for BMI.
Total cholesterol, LDL and HDL cholesterol, triglyceride and uric acid
concentrations did not differ significantly between the two groups.
In the pre-eclamptic/eclamptic group, fasting serum insulin correlated positively
with serum triglyceride (r = 0.59; P < 0.01), BMI (r = 0.54; P < 0.01) and systolic (r =
0.69; P < 0.001) and diastolic (r = 0.47; P < 0.05) blood pressure. All these variables
remained significant even when analysed in the multiple regression model.  The AUC
for insulin in the pre-eclamptic/eclamptic group correlated positively with serum
triglycerides (r = 0.57; P < 0.01), BMI (r = 0.49; P < 0.05) and systolic blood pressure
(r = 0.53; P < 0.05) and negatively with HDL2-cholesterol (r = -0.48; P < 0.05).  The
AUC for insulin did not differ between those who developed pre-eclampsia or
hypertension in subsequent pregnancies and those who did not.
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7. Sex hormones and endothelial markers in women with
prior pre-eclamptic pregnancy (VII)
Women with prior pre-eclampsia were characterized by elevated serum free
testosterone levels (20.6 ± 2.2 vs.15.0 ± 0.3 pmol/L, P = 0.03), “free androgen index“
3.2 ± 0.5 vs. 1.9 ± 0.2, P = 0.04) and free testosterone / estradiol ratio (0.089 ± 0.017
vs 0.046 ± 0.006, P = 0.02).  Serum concentrations of androstenedione,
dehydroepiandrosterone sulphate, oestradiol and total testosterone were normal.
Free testosterone correlated positively with basal insulin (r = 0.52, P = 0.016),
systolic blood pressure (r = 0.69, P = 0.001), diastolic blood pressure (r = 0.62, P =
0.004), triglycerides (r = 0.55, P = 0.009) and BMI (r = 0.51, P = 0.018) in women
with prior pre-eclampsia, but not in the controls.  The study groups did not differ with
respect to SHBG, thyroxine, LH, or FSH concentrations or the LH/FSH ratio.
Plasma endothelin-1 concentrations as well as the urinary output of PGI2 and
TXA2 metabolites were similar in the two groups, and showed no correlation with
steroid hormone concentrations.
The oral glucose tolerance test resulted in a progressive fall in insulin-like growth
factor binding protein-1 (IGFBP-1) levels, but this response, as well as the basal
levels of IGFBP-1, did not differ between the study groups.  Basal serum IGFBP-1
and insulin concentrations were negatively correlated to each other (r = -0.49, P =
0.001).
VI DISCUSSION
Insulin resistance has attracted much interest in internal medicine, because it leads
to the development of CVD in otherwise healthy subjects (Reaven 1994).  Our
studies were primarily focused on evaluation of whether pre-eclampsia is
characterized by similar metabolic changes as are known to occur in insulin
resistance syndrome.  We included only nulliparous pre-eclamptic women who had
been healthy before the 20th gestational week, and whose pre-eclamptic signs had
disappeared six weeks postpartum.  Thus we are convinced that our patients had
clear-cut pure pre-eclampsia (Gifford et al. 1990).  In addition, we studied insulin and
insulin sensitivity to see if they may be factors in some other variables which have
been linked to insulin resistance or vascular disorders outside pregnancy.  Finally, we
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also studied metabolic and endocrine changes 17 years after pre-eclamptic
pregnancy in order to see if insulin resistance and other signs possibly associated
with it prevail in women with a history of pre-eclampsia.
To assess insulin sensitivity we used the Minimal Model technique, which is a
representative and reliable method for this purpose (Bergman 1989).  The Minimal
Model has the advantage of measuring insulin sensitivity in terms of fractional
glucose disappearance rates, which should remain independent of the changes in
body composition during pregnancy (Buchanan 1997).  An additional obstacle to the
study of insulin sensitivity in pregnancy is the decrease in insulin sensitivity over the
course of gestation (Cousins 1991).  It has been reported that Minimal Model
analysis may yield negative values for insulin sensitivity in severe insulin resistance
(Saad et al. 1994), but negative values in the Minimal Model did not appear in this
study.  The hyperinsulinaemic euglycaemic clamp shows better reproducibility in non-
pregnant individuals than do other methods (coefficient of variation 10%) (DeFronzo
et al. 1979), but its use in pregnant women is not without problems.  Changes in body
composition and weight complicate the measurement of insulin sensitivity by means
of the hyperinsulinaemic euglycaemic clamp method during pregnancy.  Although
correlation between insulin sensitivities assessed by the Minimal Model and
hyperinsulinaemic euglycaemic clamp-derived values may be poorer in late
pregnancy than in non-pregnant women, both methods give comparable results
showing good correlation (r = 0.58) in pregnancy (Buchanan 1997).
Insulin sensitivity in pre-eclampsia was 37% lower than that in normotensive
pregnancy.  This new finding is in line with previous data on elevated fasting insulin
(Kaaja et al. 1995, Martinez Abundis et al. 1996) and post-load insulin levels
(Martinez Abundis et al. 1996, Lorentzen et al. 1998) in pre-eclampsia.  It is also
known that the incidence of pre-eclampsia is increased in insulin-resistant states
such as GDM (Suhonen and Teramo 1993) and obesity (Ros et al. 1998) which may
suggest that decreased insulin sensitivity precedes the onset of pre-eclampsia.
However, the data on decreased insulin sensitivity in pre-eclampsia are not uniform,
since both normal (Caruso et al. 1999) and increased (Roberts et al. 1998) insulin
sensitivity have been reported.  Different methods, different populations, and
heterogeneous origin of pre-eclampsia (placental and maternal factors) may be
explanations for the discrepant results.
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The cause of decreased insulin sensitivity in normal pregnancy (Cousins 1991) is
unknown, but several pregnancy-associated hormones, such as human placental
lactogen, cortisol, oestrogens, progesterone and prolactin may be involved (Ryan
and Enns 1988, Murai et al. 1997).  Elevated levels of FFAs may also contribute to
the decreased insulin sensitivity (Sivan et al. 1998), as does sympathetic over-activity
(Schobel et al. 1996, Manyonda et al. 1998), which characterises pre-eclampsia.
These physiological responses to pregnancy may be exaggerated or otherwise
altered in pre-eclampsia so that they may become responsible for the decreased
insulin sensitivity in these women.  One hypothesis explains decreased insulin
sensitivity in pre-eclampsia through increased FFA levels and lipid oxidation, which
together with increased cytokine levels may enhance insulin-independent glucose
transport via the hexosamine pathway.  In obesity, elevated serum free fatty acid
concentrations and enhanced lipid oxidation (Groop et al. 1992) induce skeletal
muscle insulin resistance by increasing the flux of glucose into the hexosamine
pathway (Hawkins et al. 1997), and obesity is a known risk factor as regards pre-
eclampsia.  Hexosamines inhibit the insulin-dependent glucose transport protein
(GLUT) 4, the predominant glucose transporter in anabolic conditions (Ebeling et al.
1998).  If glucose enters the cell via the insulin-independent GLUT 1 and activates
hexosamine pathway, this hypothesis can also explain why insulin resistance may be
associated with fasting hypoglycaemia, as was the tendency in present study.
Insulin-dependent glucose transport may be already impaired in women predisposed
to pre-eclampsia.  Impaired glucose phosphorylation, catalyzed in muscle by
hexokinase (HK) II, has been suggested to contribute to insulin resistance in obesity
and NIDDM (Pendergrass et al. 1998).
Decreased insulin sensitivity may impair endothelial cell function by decreasing
PGI2 production (Axelrod 1991), or by increasing ET-1 production (Ferri et al. 1996).
Another factor could be the effect of insulin resistance on lipids and lipoproteins, such
as increased VLDL secretion, affecting endothelial cell function and favouring
vasoconstriction (Sattar et al. 1996).  It is not known whether insulin resistance in
pre-eclampsia is a cause or a consequence of endothelial dysfunction.  Substances
such as nitric oxide donors and antioxidants may be useful tools to study these
relationships.
Our finding of decreased insulin sensitivity in the postpartum period in Finnish pre-
eclamptic women is in agreement with some previous data on Chinese women (Fuh
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et al. 1995), obtained two months postpartum by means of the insulin suppression
test.  However, our results are in disagreement with data on African-American
women (Jacober et al. 1994) obtained 3-6 months postpartum with the
hyperinsulinaemic-euglycaemic clamp technique.  These discrepancies might be
explained by differences in methods of measuring insulin sensitivity, or in intervals
between delivery and each study.  A difference in race can also be a confounding
factor.
Our data show that leptin concentrations are elevated in pre-eclampsia.  Leptin is
eliminated mainly through the kidneys (Stenvinkel et al. 1997, Merabet et al. 1997),
and pre-eclampsia can be accompanied by reduced renal blood flow and a reduced
glomerular filtration rate (August 1993).  The correlation between serum leptin and
proteinuria in our patients suggests an association, either direct or indirect, between
the elevation in serum leptin levels and renal changes in pre-eclampsia, although it
must be understood that proteinuria in pre-eclampsia is not a sign of renal
insufficiency, and in effect, none of our patients had renal insufficiency.  It is also
possible that elevated leptin levels in pre-eclampsia are due to release from placental
sources (Masuzaki et al. 1997, Mise et al. 1998) perhaps as a reaction to placental
hypoxaemia (Mise et al. 1998).  However, in our study leptin levels were not
associated with the birth weight, placental weight or Apgar scores.
It was a curious and new finding that leptin levels remained elevated in pre-
eclamptic women up to three months after delivery.  Our data are the first to show
that insulin sensitivity is not associated with leptin levels in pregnancy.   However,
such an association exists in non-pregnant subjects (Segal et al. 1996, Haffner et al.
1997).  It is possible that during pregnancy placental leptin production may have
masked an association between insulin sensitivity and leptin, and this gains support
from an association with insulin sensitivity in puerperal women who had had pre-
eclampsia.  Taken as a whole, our data suggest that hyperleptinaemia might be listed
among the metabolic alterations characteristic of women with prior pre-eclampsia.
Plasma homocysteine levels in pre-eclamptic patients were on average 1.8 times
higher than those in control women.  This finding in a Finnish population appears to
be in agreement with data from the USA (Rajkovic et al. 1997, Powers et al. 1998).
However, the demonstration of a relationship between homocysteine levels and
severity of pre-eclampsia, and an inverse correlation between plasma homocysteine
and insulin sensitivity are new findings.  We do not know whether or not this is a
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cause and effect relationship reflecting perhaps some common factor in vascular
physiology.  Probably this connection is based on long-term effects, since at dramatic
short-term changes in circulating glucose and insulin during Minimal Model failed to
affect homocysteine levels.
Maternally derived homocysteine is transported by the placenta into the umbilical
vein, where it is extracted by the foetus (Malinow et al. 1998).  This could explain the
inverse correlation between infant birth weight and maternal plasma homocysteine in
our study; reformation of methionine from homocysteine for foetal demands may
have been less in pre-eclamptic women with smaller foetuses.  A relative reduction in
vitamin B12 concentrations in pre-eclampsia, as seen in our patients, may contribute
to this effect, because vitamin B12 is essential for the reformation of methionine from
homocysteine (Welch and Loscalzo 1998).  It is also possible that a common
mutation in the methylenetetrahydrofolate reductase gene associated with higher
homocysteine levels (Sohda et al. 1997) could have been more frequent pre-
eclamptic women than controls.  The frequency of homozygosity of this mutation is in
the order of 5-10% in different European populations (Gudnason et al. 1998).  It
appears unlikely, however, that many of our pre-eclamptic patients would have had
this mutation, since no difference emerged in plasma homocysteine values between
the groups at postpartum examination.  This does not exclude the possibility that
these women could have had a genetic factor or some other tendency leading
towards elevated levels of homocysteine, something which perhaps can be
determined only with the aid of a methionine-loading test (Dekker et al. 1995).
Serum concentrations of activin A, inhibin A and pro-αC are markedly elevated in
pre-eclampsia, and we found these elevations to be related to the amount of
proteinuria.  Our data failed to show any conclusive relationship between insulin
sensitivity and activin A, inhibin A, or pro-αC in pre-eclampsia.  Moreover, acute, and
dramatic rises in insulin and glucose during the testing of insulin sensitivity did not
affect the circulating levels of these glycoproteins during the subsequent 160-180
minutes, either in pre-eclampsia or in normal pregnancy.  In contrast to the results of
one previous study (Muttukrishna et al. 1997), we observed significant overlapping of
the levels of activin A and inhibin A between pre-eclamptic and normotensive
pregnancies, a fact which may decrease the value of these tests in the diagnosis of
pre-eclampsia.  Differences in stage of pre-eclampsia or in genetic background
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affecting both pre-eclampsia and these proteins, or small sample sizes, may explain
these discrepancies.
Metoprolol given for more than 3 months is associated with a 14 to 22% decrease
in insulin sensitivity in men and non-pregnant women with essential hypertension
(Haenni and Lithell 1994, Jacob et al. 1996), whereas isradipine, on the other hand,
has been considered to be neutral in this regard (Brogden and Sorkin 1995).  Our
data show that short-term isradipine and metoprolol treatment had no detrimental
effects on insulin sensitivity or serum lipid and lipoprotein levels in pre-eclamptic
pregnancies.  Sympathetic over-activity (Schobel et al. 1996) and pre-existing insulin
resistance, as shown in our study, may have prevented any possible adverse effect
of metoprolol on insulin sensitivity in pre-eclampsia.  Our patients were insulin
resistant, and it has been suggested that the β-blocker-induced reduction in insulin
sensitivity may be greater in patients with higher initial insulin sensitivity (Malminiemi
et al. 1997).  It is also possible that both isradipine and metoprolol may have
prevented the possible worsening of insulin resistance, along with the progression of
pre-eclampsia, as seen by a rise in uric acid, but to exclude this possibility we would
have had to have had a control group of pre-eclamptic patients followed without
antihypertensive treatment.  For ethical reasons this was not possible.
Increases in serum triglycerides and decreases in HDL cholesterol have been
reported during β-blocker treatment in non-pregnant women (Ames 1986), but this
does not occur in pre-eclamptic patients, as observed in our study.  In contrast, HDL2
cholesterol concentrations increased during the short-term treatment with isradipine.
This effect of isradipine may be beneficial for endothelial cell function, and, for
example, it may stimulate vasodilatory PGI2-release from vascular endothelium
(Pomerantz et al. 1985, Kaaja et al. 1995, Tamagaki et al. 1996).
The concentrations of FFAs in serum were elevated in pre-clampsia in the present
study. The cause of this change cannot be explained by the present data, but it may
be possible that this is one sign of insulin resistance on the adipocytes.  It was,
however, curious that the levels of FFA reduced markedly during OGTT. This could
perhaps be seen as a piece of evidence that hormone sensitive lipase could be
suppressed by high levels of insulin following glucose challenge.
Women with a history of pre-eclampsia, studied 17 years after their first
pregnancy, were characterized by elevated fasting insulin levels, an exaggerated
insulin response in the OGTT, and elevated systolic and diastolic blood pressures.
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These findings suggest that women who once had had pre-eclampsia, may have
insulin resistance.  In the pre-eclamptic group the magnitude of hyperinsulinaemia
(and thus perhaps insulin resistance) correlated negatively with HDL cholesterol, but
positively with triglyceride concentrations and with systolic and diastolic blood
pressure.  Lipid and lipoprotein concentrations did not differ significantly.  It is
possible that the ability of insulin to stimulate the uptake and disposal of glucose by
peripheral tissues precedes the changes in lipid and lipoprotein levels.
We found mild hyperandrogenism, reflected in increased free testosterone, an
increased free androgen index and an increased free testosterone/oestradiol ratio in
women with prior pre-eclampsia.  These changes could result from increased ovarian
testosterone production or decreased circulating SHBG levels, or both, but our data
do not allow us to deduce the initial cause of these changes.  Regardless of the
cause of testosterone changes, and of the presence of normal androstenedione
levels, we feel that our patients had slight ovarian hyperandrogenism.  We do not
know which of the two major abnormalities, hyperinsulinaemia or high levels of
testosterone, is the primary change.  Insulin stimulates the production of testosterone
by ovarian tissue in vitro (Barbieri et al. 1986), which suggests that hyperinsulinaemia
could be the primary change which triggeres increased release of testosterone.  On
the other hand, androgens are known to decrease both hepatic removal of insulin
and peripheral sensitivity to insulin (Peiris et al. 1987), which suggests that
hyperandrogenism could lead to hyperinsulinaemia.  Similar coexistence of
hyperinsulinaemia and hyperandrogenism is present in PCOS and these patients
appear to be at an increased risk of pre-eclampsia (Diamant et al. 1982).  This
suggests that hyperandrogenism could precede the onset of pre-eclampsia.
Moreover, it has been reported that administration of phosphoglycan, which
increases the action of insulin, improves ovulatory function, and decreases serum
androgen concentrations, blood pressure, and plasma triglycerides in women with
PCOS (Nestler et al. 1999).
Prostacyclin and TxA2 are important in pregnancy physiology and in pre-eclampsia
(Ylikorkala and Viinikka 1992) in which ET-1 production can also be elevated (Taylor
et al. 1990).  Our data are the first demonstration that PGI2 deficiency and/or TxA2 or
ET-1 dominance, which characterize pre-eclamptic pregnancy (Ylikorkala and
Viinikka 1992) have totally vanished within 17 years after pregnancy.  Thus, these
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vascular factors are not likely to account for the increased risk of CVD in these
women (Jónsdóttir et al. 1995, Hannaford et al. 1997).
VII SUMMARY AND CONCLUSIONS
We studied whether the metabolic characteristics of so-called insulin resistance
syndrome are associated with acute pre-eclampsia and prevail after pre-eclamptic
pregnancy.  To this end, insulin sensitivity was measured by the intravenous glucose
tolerance test (the Minimal Model method) in 31 women with pre-eclampsia and 16
women with normotensive pregnancy.  In pre-eclampsia, insulin sensitivity is reduced
on average by 37%, whereas serum FFA and triglyceride concentrations are
elevated.  Insulin sensitivity was reduced by 26% three months after delivery.  Serum
leptin, also possibly a part of the insulin resistance syndrome, was 73% higher in pre-
eclamptic women than in control women, and correlated with the level of proteinuria.
Leptin concentrations were related to those of insulin both in pre-eclampsia and
normal pregnancy, but not to insulin sensitivity.  Serum concentrations of leptin
remained elevated in puerperal women with prior pre-eclampsia, and only in these
women did they show a relationship to insulin sensitivity.  Concentrations of plasma
homocysteine, a detrimental vascular factor outside pregnancy, was 76% higher in
pre-eclamptic women, and they showed a significant relationship to the level of
proteinuria.  Homocysteine levels were negatively related to insulin sensitivity in pre-
eclamptic women, but unaffected by dramatic changes in glucose and insulin levels
during Minimal Model testing.  Activin A, inhibin A and pro-αC are placentally derived
glycoproteins which were elevated in pre-eclampsia, but in no relationship to insulin
sensitivity.  The calcium channel blocker isradipine and the β-blocker metoprolol did
not affect insulin sensitivity, but isradipine increased HDL2 cholesterol concentrations
in pre-eclamptic women.
Twenty-two women with prior pre-eclampsia (17 years earlier) and 22 control
women were studied by way of a standardized oral glucose tolerance test.  Fasting
insulin levels were elevated by 33%, 3-hour insulin levels were elevated by 58%, and
the area under the insulin curve was increased by 33% in women with prior pre-
eclampsia.  Lipid and lipoprotein concentrations were normal.  In addition, these
women had elevated serum free testosterone levels (37%), an elevated free
androgen index (68%), and an elevated free testosterone to oestradiol ratio (93%).
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The levels of insulin-like growth factor-binding protein-1, FSH, LH, androstenedione,
dehydroepiandrosterone sulphate and ET-1 as well as urinary output of PGI2 and
TxA2 metabolites were normal in these women.
Our studies show evidence that pre-eclampsia is a state of increased insulin
resistance, which persists for at least three months after pregnancy but may do so for
up to 17 years.  High leptin and, homocysteine levels may be reflections, at least in
part, of altered glucose homeostasis in pre-eclampsia.  Isradipine and metoprolol
have no detrimental effect on insulin sensitivity and can be safely used, from this
point of view, in pre-eclampsia.  The data of the present study do not allow to deduce
whether insulin resistance in pre-eclamptic women is a primary change, or whether it
is secondary e.g. to endothelial dysfunction.  Increased insulin levels after pre-
eclamptic pregnancy, as seen in present study, may suggest that the insulin
resistance is an inherent property in women with pre-eclampsia.  The data imply that
insulin resistance may perhaps be an aetiopathogenetic factor in pre-eclampsia,
prevailing long after pregnancy, and perhaps explaining the increased incidence of
cardiovascular morbidity in these women.
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